Anebulo Pharmaceuticals, Inc
We are a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration.
$6.00 - $8.00
May 7, 2021
THE BENCHMARK COMPANY, LLC
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for Anebulo Pharmaceuticals, Inc IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277